98 results about "2-Pyridone" patented technology

The present invention provides compounds having an agonistic activity to the cannabinoid receptor, which is represented by the formula (I): wherein R¹ is optionally substituted C1-C8 alkyl and the like; R² is C1-C6 alkyl; R³ is C1-C6 alkyl and the like; or R² and R³ taken together with the adjacent carbon atoms may form an optionally substituted 5 to 10 membered non-aromatic carbon ring; R⁴ is hydrogen and the like; G is a group selected from the groups shown by the formula and the like: wherein R⁵ is hydrogen and the like; X¹ is a single bond and the like; X² is optionally substituted C1-C8 alkylene that may be replaced by one or two groups of -O-, or -N(R⁶)-, wherein R⁶ is hydrogen, and the like; X³ is a single bond and the like; a pharmaceutically acceptable salt or a solvate thereof, and pharmaceutical compositions, atopic dermatitis treating agents, and anti-pruritus agents, especially anti-pruritus agents for oral use and for external application, which each contains the said compound as an active ingredient.

The present invention relates to 5-substituted-4-(substituted)phenylamino-2-pyridone derivatives, pharmaceutical compositions and methods of use thereof.

The invention provides compounds of formula

wherein R¹, R³, R⁴, R⁵, R⁶, R⁷, L, X and Y are as defined in the specification; together with processes and intermediates for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.

A method of treating a mammal with an epileptic condition, comprising: administering to said mammal a pharmaceutical composition containing an effective amount of an N-phenyl substituted 2-pyridone compound and/or pharmaceutically acceptable salts thereof.

The invention discloses a picoxystrobin preparation method. The picoxystrobin preparation method comprises the following steps: (1) dissolving a compound (I)3-isochromanone in methyl alcohol and first inert solvent, and reacting so as to obtain (III) (2-halogenated methyl phenyl) methyl acetate; (2) converting (II) 6-trifluoromethyl-2-pyridone into sodium salt, reacting with quaternary ammonium salt in a polar solvent, and then adding the (III) (2-halogenated methyl phenyl) methyl acetate, thus obtaining (IV) 2-[2'-(6'-tirfluoromethylpyridine-2-oxyl) methyl] phenyl methyl acetate; (3) carrying out aldolization on the (IV) 2-[2'-(6'-tirfluoromethylpyridine-2-oxyl) methyl] phenyl methyl acetate and a formamide compound, and hydrolyzing so as to obtain (V) 2-[2'-(6'-tirfluoromethylpyridine-2-oxyl) methyl] phenyl-3-hydroxyl methyl acetate; and (4) treating the (V) 2-[2'-(6'-tirfluoromethylpyridine-2-oxyl) methyl] phenyl-3-hydroxyl methyl acetate by using alkali and a methylation reagent so as to obtain picoxystrobin.

Problem: To provide an optical recording medium having a recording layer improved in light stability that is capable of writing and reading of high-density optical information by a short-wavelength laser beam.

Means for Solving the Problems: There is provided an optical recording medium with a recoding layer comprising an organic dye compound, wherein the recording layer contains a metal complex compound composed of a pyridone azo compound represented by the following the general formulas [I] to [III] and a divalent ion of metal coordinated to it such as nickel, cobalt, iron, zinc, copper, manganese and the like, wherein the pyridone azo compound contains a 6-hydroxy-2-pyridone structure as a coupling component and isoxazole, 1,2,4-triazole or pyrazole structure as a diazo component.

(In the general formulas [I] to [III], R₁ to R₁₀ each is independently a hydrogen atom or monovalent functional group.)

The present invention provides a 4-oxoquinolizine antibacterial agent having a 2-pyridone skeleton as a partial structure and also having a strong antibacterial effect on gram-positive bacteria, gram-negative bacteria or anaerobic bacteria. The compound having the following formula (I) or a pharmaceutically acceptable salt thereof:

wherein:

• • R₁ represents hydrogen atom or a carboxyl-protecting group,
  • R₂ represents hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxyl group or hydroxyl group,
  • R₃ represents phenyl group or an aromatic substituent selected from the group consisting of 5-membered and 6-membered heterocyclic groups and R₃ has a substituent selected from the group consisting of a hydrogen atom, a lower alkyl group, a lower alkoxyl group, a nitro group, a cyano group, an amino group, an acyl group, a carbamoyl group and a ureido group, and
  • R₄ represents a hydrogen atom or a halogen atom.

The invention relates to a cyanide-free silver plating solution additive which comprises the following components by ratio: 0.1-10g/ l of brightener, 5-10g/ l of leveling agent, 100-600g/ l of complexing agent and the balance of plasma water, wherein the brightener is one or mixture of more in nitrogen-containing compound, triazole, benzotriazole, 2-hydroxypyridine, pyridine, 22 dipyridyl, 1, 10-phenanthroline, triethylene tetramine and diethylene triamine according to any ratio; the leveling agent is one or mixture of more in aromatic hydrocarbon compounds, naphthalene, 1-methylnaphthalene, 1, 4-naphthoquinone and 1-naphthol according to any ratio; the complexing agent is one or mixture of more in disodium ethylenediamine tetraacetate, niacin, aminosulfonic acid and potassium pyrophosphate according to any ratio. The cyanide-free silver plating solution additive has the beneficial effects that the plating solution is stable, low in toxicity and good in dispersing ability; the obtained plating layer is bright and fine as well as good in binding force; the technology adopts the environment-friendly organic additive which does not contain heavy metal and sulfide; the plating layer is good in corrosion resistance. Furthermore, the cyanide-free silver plating solution additive can be directly used for parts such as brass, copper, chemical nickel and the like, preplating is not needed, and the binding force is also guaranteed.

There are provided novel compounds of formula (I), wherein R¹, R², R⁴, R⁵, G¹, G², L, Y and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of neutrophil elastase.

There are provided novel compounds of formula (I), wherein R¹, R², R⁴, R⁵, G¹, G², L, Y and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of neutrophil elastase.

The invention relates to a preparation method of palbociclib. The method comprises the following steps: carrying out N-acetoacetylation reaction by using cyclopentylamine and an acetoacetylation agent to obtain N,N-di(acetoacetyl) cyclopentylamine (II), carrying out intramolecular condensation on N,N-di(acetoacetyl) cyclopentylamine (II) in the presence of an alkaline reagent to obtain N-cyclopentyl-3-acetyl-4-methyl-6-hydroxy-2-pyridone (III), enabling N-cyclopentyl-3-acetyl-4-methyl-6-hydroxy-2-pyridone (III) to react with a formylation reagent to prepare N-cyclopentyl-3-acetyl-4-methyl-5-formyl-6-chlorine-2-pyridone (IV), carrying out pyrimidine ring reaction by using N-cyclopentyl-3-acetyl-4-methyl-5-formyl-6-chlorine-2-pyridone (IV) and N-(5-(4-tert-butoxy carbonyl-1-hexahydropyrazinyl)-2-pyridyl) guanidine sulfate (V), and then hydrolyzing under the alkaline condition to prepare palbociclib. The preparation method of palbociclib is easily available in raw materials, short in process, simple and convenient to operate and safe and environmentally friendly in process.

Compounds of Formula (I) are effective in the treatment of a microbial infection.

Described are a series of 2-pyridone compounds as a potent and selective new class of type II topoisomerase inhibitors with broad-spectrum antimicrobial activity having the general formula (I); where R1, R2, X, and Y are defined herein Such compounds can be used in methods for treating an infection caused by a gram-positive pathogen, a gram-negative pathogen, or a drug-resistant strains thereof.

The invention relates to a determination reagent of a total bile acid. The reagent comprises two components, wherein the reagent 1 comprises a phosphate buffer, Thio-NAD (Nicotinamide Adenine Dinucleotide), Emulgen B-66 CTAB (Cetyltrimethyl Ammonium Bromide), NaCl, 2-hydroxypyridine-N-oxide; the reagent 2 comprises a glycinate buffer, dextran sulfate, EGTA (Ethylene Glycol Tetraacetic Acid), 3 alpha-HSD (Hydrogen Sterol Dehydrogenase), Emulgen B-66, NADH (Nicotinamide-adenine Dinucleotide Acid), and 2-hydroxypyridine-N-oxide. As the combination of the cation surfactant and the nonionic surfactant Emulgen B-66 is added, the interference of bilirubin can be effectively eliminated; the selected stabilizer is added in the product, so that the reagent can be stored for one year at 2-8 DEG C without influence on the properties; the substrate concentration and the ion strength can be adjusted to enable the recovery rate of the reagent to be more than 98%. The determination reagent disclosed by the invention has the advantages of high accuracy in determined results, strong anti-interference performance, good stability and the like.

The invention discloses a preparation method of an important intermediate: 2-hydroxypyridine-N-oxide with the CAS Number of 13161-30-3. The invention reports a new synthetic route applicable to industrial production, which comprises the following steps: under catalysis of a catalyst generated in-situ, oxidizing 2-chloropyridine with hydrogen peroxide (30%) to generate an N-oxide, and then hydrolyzing under an alkaline condition to directly generate the target product. The preparation method greatly improves the yield, realizes one-pot reaction, greatly reduces generation of organic waste liquor and realizes environmental protection.

The invention belongs to the chemical field of medicine synthesis, and relates to an asymmetric catalytic hydrogenation method for 2-pyridinone compounds. The asymmetric catalytic hydrogenation method includes steps of firstly, enabling chiral ligand and metal rhodium precursors to react with one another in organic solvents for 0.5-2 hours at the temperatures of 20-40 DEG C to obtain in-situ catalysts; secondly, arranging reaction systems in an autoclave, adding the 2-pyridinone compounds into the autoclave, enabling the reaction systems and the 2-pyridinone compounds to react with one another for 20-24 hours in hydrogen atmosphere at the reaction temperatures of 0-50 DEG C under the hydrogen pressures of 2-50 atmospheric pressures. The chiral ligand is (R)-Binapine. The asymmetric catalytic hydrogenation method has the advantages that the asymmetric catalytic hydrogenation method is high in catalytic efficiency, and products can be quickly obtained within short time under low-pressure conditions; only a few catalysts are utilized; most 2-pyridone substrates can have conversion rates of 99% and the optimal stereoselectivity of 99%, and accordingly the asymmetric catalytic hydrogenation method has an excellent industrial prospect.

The invention provides a 2-aminopyridine derivative containing a 2-pyridone ring side chain or an enantiomer of the 2-aminopyridine derivative. The target compound is obtained mainly by taking 2-aminopyridine as a parent nucleus to be coupled with a 4-bromo-2-pyridone ring. Experiments prove that the 2-aminopyridine derivative has a significant proliferation inhibition effect on tumor cells Karpas 299 (NPM-ALK positive cell lines) related to the ALK tyrosine kinase activity, NCI-H2228 (EML4-ALK positive cell lines), SKN-BE2 (ALK gene amplification cell lines) and SH-SY5Y (ALK F1174 mutant cell lines) and can be prepared into corresponding anti-tumor-cell drugs. The 2-aminopyridine derivative has a general structural formula I (please see the formula in the description).

The invention relates to a hydroxylation method of a halogenated aromatic compound. The method takes a 2-pyridone compound as a ligand additive and takes CuI as a catalyst, under existence of a phase-transfer catalyst and a solvent, MOH and the halogenated aromatic compound are subjected to a hydroxylation reaction under mild condition, the reaction yield is high, and an application scope of a substrate is wide. Compared with same types of reactions reported in literature, the reaction condition of the provided method is mild, the yield is high, and the method has good application prospect. the hydroxylation reaction of an iodo aromatic compound can be carried out in an aqueous solution at the temperature of 90 DEG C, and a hydroxylated product with high yield can be obtained, the reaction temperature is averagely reduced by about 30 DEG C by comparing with a report in the literature; the hydroxylation reaction of a brominated aromatic compound can be carried out in the aqueous solution at the temperature of 120 DEG C, and the reaction temperature is averagely reduced by about 20 DEG C by comparing with the report in the literature.

2-Pyridone compounds represented by general formula [1], tautomers or stereoisomer thereof, pharmaceutically acceptable salts of the same, or solvates thereof have excellent GK-activating activity and therefore are useful as drugs. In general formula [1], A is a benzene ring or a pyridine ring; X is a structure represented by general formula [3]; V is a single bond or lower alkylene; W is a single bond, an ether linkage, or lower alkylene (which may contain an ether linkage).

A 1,4-dihydroxy-6-methyl-2-pyridone compound having structural formula (I), and a preparation method and application thereof are provided. The compound has good antibacterial activity in vitro against bacteria such as staphylococcus aureus, streptococcus, Escherichia coli, and has a stronger antibacterial activity against Gram-positive bacteria than against Gram-negative bacteria; and also has good antibacterial activity against fungi such as Candida albicans and Candida Krusei, so that the compound can be used as a drug for preventing and curing bacterial and fungal infections.